CNS Drug Discoveries: Schizophrenia Chapter

Published by: Espicom Healthcare Intelligence

Published: Aug. 14, 2008 - 84 Pages

Table of Contents

SCHIZOPHRENIA

EXECUTIVE SUMMARY

THE.FACTS

What.is.schizophrenia.and.why.are.we.interested.in.it?

Symptoms Associated with Schizophrenia

Schematic Depicting Mood Swings in Bipolar Disorder

PATIENT STATISTICS

Incidence,.diagnosis.rates.and.treatment;.now.and.in.the.future

PATIENT MODEL

Summary of Patient Population Forecasts 2007A-2014E

Model.Assumptions

DRUG GROWTH DRIVERS

DRUG GROWTH RISKS/DAMPENERS

THE.SCHIZOPHRENIA.MARKET

Global CNS Market 2007 (US$91.9 billion)

Global Sales Split (2006)

The.Major.Players

Market Share of Antipsychotic Players by Sales (Dec 2007A)

Players.and.Products.in.2007

Players.and.Products.in.2014

Market Share of Antipsychotic Players by Sales (Dec 2014E)

CURRENT.TREATMENTS

Leading.Brands

Comparison of Leading Antipsychotic Drugs

Current.Products'.Patent.Exposure

Patent Exposure of Leading Antipsychotic Brands

ANALYSIS OF LEADING BRANDS

Atypical.Antipsychotics

Abilify

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Geodon/Zeldox

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Invega

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Lonasen

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Clinical Efficacy of Blonanserin

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Risperdal

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Seroquel

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Zyprexa

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Other.Atypical.Antipsychotics

Serdolect

Lullan

Clozaril/Leponex

Solian

GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E

Sales Forecasts of Current Leading Antipsychotics

Model.Assumptions

NEW.DRUGS.IN.R&D

Drugs in Development to Treat Schizophrenia and Bipolar Disorder

ANALYSIS OF LATE-PHASE DRUGS

Drugs in Late-Phase Development to Treat Schizophrenia and Bipolar Disorder

D/5-HT.Receptor.Antagonists

Asenapine

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Bifeprunox

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Lurasidone

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Fanapta

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Safety Profile of Iloperidone vs Approved Antipsychotics

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

GLOBAL SALES FORECASTS OF LATE-PHASE SCHIZOPHRENIA DRUGS 2008E - 2014E

Sales Forecasts of Late-Phase Developmental Antipsychotic Drugs

Model.Assumptions

ANALYSIS OF PHASE II DRUGS

BL-1020

Cariprazine

EVP-6124

MEM 3454

LY2140023

Vabicaserin

COMPETITOR.RATIO.ANALYSIS

COMPETITOR RATIO ANALYSIS - PRODUCTS

CR Analysis of Antipsychotic Agents Approved by 2014 - Based on Drug Class

COMPETITOR RATIO ANALYSIS - COMPANIES

CR Analysis of Antipsychotics Approved by 2014 - Based on Company

WINNERS & LOSERS

Summary of Key Companies and Drugs in the Antipsychotic Market by 2014

Winners

Losers

DISCONTINUATION.OF.DRUGS

Antipsychotic Drugs Discontinued from Clinical Development

SCHIZOPHRENIA.APPENDIX.1

ASSESSMENT OF ANTIPSYCHOTIC EFFICACY IN SCHIZOPHRENIA

ASSESSMENT OF ANTIPSYCHOTIC EFFICACY IN BIPOLAR DISORDER

SCHIZOPHRENIA.APPENDIX.2

PHASE TRANSITION PROBABILITY

Probability of Launch

SCHIZOPHRENIA.APPENDIX.3

PATIENT MODEL

Summary of US Schizophrenia Patient Population Forecasts

Summary of European (Top 5) Schizophrenia Patient Population Forecasts

Summary of Japanese Schizophrenia Patient Population Forecasts

SCHIZOPHRENIA.APPENDIX.4

GLOBAL ANTIPSYCHOTIC DRUG SALES 2007A-2014E

SCHIZOPHRENIA.APPENDIX.5

COMPETITOR RATIO ANALYSIS CRITERIA

Key Antipsychotic Drugs on the Market by 2014

SCHIZOPHRENIA.GLOSSARY

SCHIZOPHRENIA.REFERENCES

ACRONYMS

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.